Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570414 | 0.88 | GRIA1 (0.43) | GRIA1GRIA3S1PR1S1PR3SLC7A11 | |
| SCHEMBL28240463 | 0.85 | GRIA1 (0.41) | GRIA1GRIA3SLC7A11HCAR2PPARA | |
| SCHEMBL2569102 | 0.84 | S1PR1 (0.37) | S1PR1S1PR3RAB9AHPGDALDH1A1 | |
| SCHEMBL16508623 | 0.83 | GRIA1 (0.44) | GRIA1GRIA3S1PR1S1PR3SLC7A11 | |
| SCHEMBL16571451 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3SLC7A11RAB9AHPGD | |
| SCHEMBL13285297 | 0.74 | S1PR1 (0.36) | S1PR1S1PR3RAB9AHPGDALDH1A1 | |
| SCHEMBL1227029 | 0.72 | S1PR1 (0.41) | GRIA1GRIA3S1PR1S1PR3SLC7A11 | |
| SCHEMBL2570427 | 0.72 | RAB9A (0.35) | S1PR1S1PR3SLC7A11RAB9AHPGD | |
| SCHEMBL2565733 | 0.71 | NPSR1 (0.36) | S1PR1GAARAB9AHPGDALDH1A1 | |
| SCHEMBL16571684 | 0.71 | GRIA1 (0.44) | GRIA1GRIA3S1PR1SLC7A11HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2382212-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010085581-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085581-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | S1PR4, S1PR3, S1PR1 | GRIA1 716/4885GRIA3 1036/4885S1PR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.